Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6967MR)

This product GTTS-WQ6967MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6967MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2056MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ12942MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ950MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ7115MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ6797MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ9754MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ15924MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ15623MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAY-736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW